Table 5.
Univariate analysis and Multivariate analysis of prognostic factors in MDA5+DM patients.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P- value | HR (95%CI) | P- value | |
| Female | 0.420(0.095–1.852) | 0.252 | ||
| Age at onset | 2.776(1.031–7.471) | 0.043* | 9.842(1.434–67.528) | 0.020* |
| Duration from onset to treatment | 0.550(0.200–1.515) | 0.247 | ||
| Mortality within 3 months | 0.000(0.000–1.845) | 0.069 | ||
| Mortality within 12 months | 0.001(0.000–1.294) | 0.059 | ||
| Smoking history | 2.309(0.743–7.171) | 0.148 | ||
| Muscle weakness | 0.616(0.231–1.644) | 0.334 | ||
| Gottron sign | 1.311(0.455–3.776) | 0.616 | ||
| Heliotrop rash | 0.598(0.193–1.856) | 0.374 | ||
| Skin ulcer | 0.384(0.087–1.689) | 0.205 | ||
| Raynaud phenomenon | 0.045(0.000–351.921) | 0.498 | ||
| Fever | 2.336(0.869–6.282) | 0.093 | ||
| Cough | 0.527(0.120–2.321) | 0.397 | ||
| Dyspnea | 2.254(0.725–7.002) | 0.160 | ||
| Pneumothorax | 2.142(0.282–16.282) | 0.462 | ||
| Concomitant neoplasia | 0.048(0.000–216181.008) | 0.698 | ||
| Neutrophil Count | 0.272(0.036–2.058) | 0.207 | ||
| Lymphocyte Count | 0.448(0.163–1.237) | 0.121 | ||
| ESR | 0.328(0.093–1.156) | 0.083 | ||
| CRP | 4.665(1.615–13.474) | 0.004* | 2.172(0.480–9.841) | 0.314 |
| CK | 5.104(0.674–38.674) | 0.115 | ||
| LDH | 36.822(0.430–3154.017.039) | 0.112 | ||
| Myoglobin | 3.004(1.124–8.031) | 0.028* | 3.347(0.783–14.306) | 0.103 |
| Albumin | 0.109(0.035–0.342) | 0.000* | 0.307(0.053–S1.785) | 0.189 |
| Ferritin | 7.897(2.862–21.793) | 0.000* | 11.255(2.084–60.786) | 0.005* |
| PCT | 2.793(1.012–7.707) | 0.047* | 0.954(0.217–4.187) | 0.950 |
| ILD diagnosis | 25.672(0.061–10818.508) | 0.293 | ||
| Reticulations | 0.630(0.179–2.210) | 0.470 | ||
| Septal thickening | 2.228(0.835–5.940) | 0.109 | ||
| Ground glass opacities | 1.202(0.388–3.730) | 0.750 | ||
| Nodules | 1.542(0.535–4.440) | 0.422 | ||
| Bronchiectasis/Bronchiolectasis | 1.413(0.186–10.712) | 0.738 | ||
| Honeycombing | 2.142(0.282–16.282) | 0.462 | ||
| Consolidation | 2.081(0.671–6.454) | 0.205 | ||
| ELVAR | 0.133(0.038–0.468) | 0.002* | 0.098(0.017–0.564) | 0.009* |
| Severity of type I respiratory failure | ||||
| Mild | 7.399(2.370–23.106) | 0.001* | 0.001(0.000–4.093E+100) | 0.995 |
| Moderate | 8.453(3.075–23.234) | 0.000* | 5.369(0.676–42.654) | 0.112 |
| Severe | 8.516(1.719–42.197) | 0.009* | 1.062(0.088–12.815) | 0.962 |
| P/F ratio | 0.095(0.030–0.298) | 0.000* | 0.000(0.000–4.865E+99) | 0.941 |
| Oxygen supplementation | ||||
| 1–2 | 3.370(0.958–11.853) | 0.058 | ||
| 3–4 | 4.802(1.542–14.954) | 0.007* | 3.476(0.286–42.194) | 0.328 |
| >4 | 3.711(1.337–10.299) | 0.012* | 0.010(0.001–0.146) | 0.001* |
| FVC | 1.000 | 1.000 | NC& | |
| DLCO | 1.000 | 1.000 | NC& | |
| ANA | 0.296(0.067–1.303) | 0.107 | ||
| SSA | 0.037(0.000–11.180) | 0.259 | ||
| SSB | 0.045(0.000–351.921) | 0.498 | ||
| RO-52 | 2.985(0.677–13.150) | 0.148 | ||
| CENP-B | 2.142(0.282–16.282) | 0.462 | ||
| Ku | 0.048(0.000–216181.008) | 0.698 | ||
| PM-Scl | 0.047(0.000–2532.428) | 0.582 | ||
| Jo-1 | 0.047(0.000–2532.428) | 0.582 | ||
| PL-7 | 0.048(0.000–216181.008) | 0.698 | ||
| PL-12 | 0.047(0.000–2532.428) | 0.582 | ||
| OJ | 4.085(0.531–31.432) | 0.176 | ||
| SRP | 0.047(0.000–2532.428) | 0.582 | ||
| TIF1-γ | 1.239(0.164–9.388) | 0.836 | ||
| Mi-2β | 2.196(0.625–7.713) | 0.220 | ||
| SAE | 0.048(0.000–216181.008) | 0.698 | ||
| Glucocorticoid | 1.831(0.665–5.043) | 0.242 | ||
| Methotrexate | 0.042(0.000–48.056) | 0.378 | ||
| Cyclophosphamide | 1.176(0.379–3.648) | 0.779 | ||
| Cyclosporine A | 0.363(0.048–2.747) | 0.326 | ||
| Tacrolimus | 0.415(0.055–3.143) | 0.395 | ||
| Plasma exchange | 2.812(0.900–8.787) | 0.075 | ||
| Single drug or Combination drugs | ||||
| 1 drug | 0.894(0.203–3.935) | 0.882 | ||
| 2 drugs | 1.119(0.254–4.923) | 0.882 | ||
| 3 drugs | 0.514(0.146–1.804) | 0.299 | ||
| ≥4 drugs | 239(0.164–9.388) | 0.836 | ||
*
P < 0.05.
&
NC, only 2 patients in early death group accepted lung function test and other 14 patients in early death group didn't accept lung function test for rapidly death or intolerable. Hence multivariate analysis didn't include the FVC and DLCO into analysis.